Supported by leading international investors led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company LONDON, June 30, 2020-- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million extended Series C financing. The financing augments Syncona’s previously announced Series C investment in Freeline of $40 million (£30.6 million) with an additional $80 million (£61.2 million) of new capital.